-
1 Comment
GlaxoSmithKline Pharmaceuticals Limited is currently in a long term uptrend where the price is trading 1.2% above its 200 day moving average.
From a valuation standpoint, the stock is 56.6% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 7.5.
GlaxoSmithKline Pharmaceuticals Limited's total revenue rose by 10.1% to $9B since the same quarter in the previous year.
Its net income has increased by 123.7% to $2B since the same quarter in the previous year.
Based on the above factors, GlaxoSmithKline Pharmaceuticals Limited gets an overall score of 3/5.
Exchange | NSE |
---|---|
Sector | Healthcare |
Industry | Drug Manufacturers - General |
CurrencyCode | INR |
ISIN | INE159A01016 |
Market Cap | 482B |
---|---|
Beta | 0.13 |
Target Price | 2617.75 |
PE Ratio | 56.18 |
Dividend Yield | 1.0% |
GlaxoSmithKline Pharmaceuticals Limited manufactures, distributes, and trades in pharmaceuticals in India and internationally. The company offers vaccines, such as Infanrix Hexa for vaccination of infants against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, and disease caused by Haemophilus influenzae type B; Synflorix for active immunization of infants against pneumococcal diseases and acute otitis media; Havrix for active immunization against disease caused by Hepatitis A virus; Menveo to prevent invasive meningococcal disease; Boostrix for immunization against diphtheria, tetanus and pertussis; Fluarix Tetra for the prevention of influenza disease; Varilrix for active immunization against varicella; and Shingrix for prevention of herpes zoster and post-herpetic neuralgia. It also provides specialty medicines comprising NUCALA for severe eosinophilic asthma, eosinophilic granulomatosis with polyangiitis, and hypereosinophilic syndrome; and TRELEGY ELLIPTA for treating chronic obstructive pulmonary disease. In addition, the company offers general medicines, including AUGMENTIN and CEFTUM, which are antibiotics to treat bacterial infections; CALPOL for treatment of mild to moderate pain; ELTROXIN for hypothyroidism; CCM to treat calcium and vitamin D deficiency; NEOSPORIN for treatment and prevention of specific bacterial skin infections; BETNOVATE for skin conditions which require relief of inflammation; T-BACT for bacterial skin infections; and PHYSIOGEL for dry skin and dry skin associated with redness and itch. Further, it develops products for infectious diseases, HIV, oncology, and immunology. The company was formerly known as SmithKline Beecham Pharmaceuticals India Ltd. and changed its name to GlaxoSmithKline Pharmaceuticals Limited in 2001. GlaxoSmithKline Pharmaceuticals Limited was incorporated in 1924 and is headquartered in Mumbai, India.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for GLAXO.NSE using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025